Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients with Melanoma

CPT: Pharmacometrics and Systems Pharmacology

Volumn 6, Issue 1, 2017, Pages 5-7

  De Greef, R ^a,b   Elassaiss Schaap, J ^a,c   Chatterjee, M ^a   Turner, D ^a   Ahamadi, M ^a   Forman, M ^a   Cutler, D ^a   De Alwis, D ^a   Kondic, A ^a   Stone, J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Certara Company   (Netherlands)

^c PD value BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PEMBROLIZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANTINEOPLASTIC ACTIVITY; CLINICAL OUTCOME; CLINICAL PHARMACOLOGY; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MELANOMA; OPEN STUDY; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SIMULATION; T LYMPHOCYTE ACTIVATION; BIOLOGICAL MODEL; COMPUTER SIMULATION; MULTICENTER STUDY (TOPIC); PROCEDURES; SKIN NEOPLASMS; STATISTICS AND NUMERICAL DATA; TRENDS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; COMPUTER SIMULATION; HUMANS; IMMUNOTHERAPY; MELANOMA; MODELS, BIOLOGICAL; MULTICENTER STUDIES AS TOPIC; SKIN NEOPLASMS;

EID: 84997270876     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1002/psp4.12131     Document Type: Review

References (14)

1. Melero, I., Berman, D.M., Aznar, M.A., Korman, A.J., Pérez Gracia, J.L., &, Haanen, J., Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat. Rev. Cancer 15, 457-472 (2015).
2. Madorsky Rowdo, F.P., Baron, A., Urrutia, M., &, Mordoh, J., Immunotherapy in cancer: A combat between tumors and the immune system; you win some, you lose some. Front. Immunol. 6, 127 (2015).
3. Keytruda (pembrolizumab) for injection, for intravenous use [package insert]. (Whitehouse Station, NJ. Merck & Co, Inc., 2015).
4. Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012).
5. Mellman, I., Coukos, G., &, Dranoff, G., Cancer immunotherapy comes of age. Nature 480, 480-489 (2011).
6. Hamid, O., et al,. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134-144 (2013).
7. Robert, C., et al,. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet 384, 1109-1117 (2014).
8. Hamid, O., et al,. Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL). J. Clin. Oncol. 32 (5 suppl), abstract #3000 (2014).
9. Ribas, A.F., et al,. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). J. Clin. Oncol. 32 (5 suppl), abstract #LBA9000 (2014).
10. Chatterjee, M.S., et al., Population pharmacokinetic/pharmacodynamic modeling of tumor size dynamics in pembrolizumab-Treated advanced melanoma. CPT Pharmacometrics Syst Pharmacol. (in press).
11. Ahamadi, M., et al., Model-based characterization of the pharmacokinetics of pembrolizumab, a humanized antiPD-1 monoclonal antibody, in advanced solid tumors. CPT Pharmacometrics Syst Pharmacol. (in press).
12. Lindauer, A., et al., Translational pharmacokinetic/pharmacodynamic modeling of tumor growth inhibition supports dose-range selection of the antiPD-1 antibody pembrolizumab. CPT Pharmacometrics Syst Pharmacol. (in press).
13. Elassaiss-Schaap, J., et al., Using model-based "learn and confirm" to reveal the pharmacokinetics-pharmacodynamics relationship of pembrolizumab in the KEYNOTE-001 Trial. CPT Pharmacometrics Syst Pharmacol. (in press).
14. Chatterjee, M., et al,. Model-based analysis of the relationship between pembolizumab exposure and efficacy in patients with melanoma and NSCLC: Across indication comparison. 2015 Annual Meeting of the Population Approach Group in Europe, June 2-5, 2015; Hersonissos, Greece.